| Troponin, where do we go from here? | |
| | |
MedLine Citation:
|
PMID: 9439882 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The development of new techniques brings new challenges of interpretation and changes in previously standard clinical paradigms, but it also provides an opportunity to markedly enhance our understanding of the processes that lead to cardiovascular pathobiology. The troponins offer great promise as a method for us to further our understanding of the pathogenesis of a variety of cardiac syndromes. |
| | |
Authors:
|
A S Jaffe |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Clinics in laboratory medicine Volume: 17 ISSN: 0272-2712 ISO Abbreviation: Clin. Lab. Med. Publication Date: 1997 Dec |
Date Detail:
|
Created Date: 1998-02-13 Completed Date: 1998-02-13 Revised Date: 2006-03-28 |
Medline Journal Info:
|
Nlm Unique ID: 8100174 Medline TA: Clin Lab Med Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 737-52 Citation Subset: IM |
Affiliation:
|
Cardiovascular Division, State University of New York Health Science Center at Syracuse, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Markers* Cardiovascular Diseases / diagnosis False Positive Reactions Humans Myocardium* Troponin* |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Troponin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Why cardiospecificity is preeminent in myocardial markers of injury.
Next Document: The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy.